Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. doi: 10.1073/pnas.1006614107. Epub 2010 Oct 18.

2.

Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.

Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L.

Elife. 2013 Apr 16;2:e00288. doi: 10.7554/eLife.00288.

3.

Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.

Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, Diem K, Jin L, Stanaway J, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, Magaret A, Koelle DM, Wald A, Corey L.

J Virol. 2014 May;88(9):4921-31. doi: 10.1128/JVI.03285-13. Epub 2014 Feb 19.

4.

Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa.

Schiffer JT, Swan DA, Magaret A, Schacker TW, Wald A, Corey L.

PLoS One. 2016 Jun 10;11(6):e0155124. doi: 10.1371/journal.pone.0155124. eCollection 2016.

5.

Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.

Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A.

JAMA. 2011 Apr 13;305(14):1441-9. doi: 10.1001/jama.2011.420.

6.

Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.

Schiffer JT, Magaret A, Selke S, Corey L, Wald A.

J Antimicrob Chemother. 2011 Nov;66(11):2593-600. doi: 10.1093/jac/dkr346. Epub 2011 Aug 24.

7.

Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.

Schiffer JT, Swan DA, Corey L, Wald A.

Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9. doi: 10.1128/AAC.01114-13. Epub 2013 Sep 9.

8.

The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.

Schiffer JT, Wald A, Selke S, Corey L, Magaret A.

J Infect Dis. 2011 Aug 15;204(4):554-61. doi: 10.1093/infdis/jir314.

9.

Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.

Çuburu N, Wang K, Goodman KN, Pang YY, Thompson CD, Lowy DR, Cohen JI, Schiller JT.

J Virol. 2015 Jan;89(1):83-96. doi: 10.1128/JVI.02380-14. Epub 2014 Oct 15.

10.

Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.

Schiffer JT, Corey L.

Nat Med. 2013 Mar;19(3):280-90. doi: 10.1038/nm.3103.

11.

Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.

Dhankani V, Kutz JN, Schiffer JT.

PLoS Comput Biol. 2014 Nov 6;10(11):e1003922. doi: 10.1371/journal.pcbi.1003922. eCollection 2014 Nov.

12.

Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L.

N Engl J Med. 2000 Mar 23;342(12):844-50.

13.

Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.

Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L.

J Exp Med. 2007 Mar 19;204(3):595-603. Epub 2007 Feb 26.

14.

A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, BenMohamed L.

Mucosal Immunol. 2009 Mar;2(2):129-143. doi: 10.1038/mi.2008.81. Epub 2008 Dec 24.

15.

Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.

Moss NJ, Magaret A, Laing KJ, Kask AS, Wang M, Mark KE, Schiffer JT, Wald A, Koelle DM.

J Virol. 2012 Sep;86(18):9952-63. doi: 10.1128/JVI.00829-12. Epub 2012 Jul 3.

16.

Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.

Tata S, Johnston C, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Infect Dis. 2010 Feb 15;201(4):499-504. doi: 10.1086/650302.

17.

Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.

Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, Corey L.

J Infect Dis. 2008 Oct 15;198(8):1141-9. doi: 10.1086/591913.

18.

Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract.

Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, Kaul R.

AIDS. 2007 Mar 12;21(5):589-98.

PMID:
17314521
19.

Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Johnston C, Corey L.

Clin Microbiol Rev. 2016 Jan;29(1):149-61. doi: 10.1128/CMR.00043-15. Review.

20.

Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret A, Wald A, Corey L.

Sci Transl Med. 2009 Nov 18;1(7):7ra16. doi: 10.1126/scitranslmed.3000193.

Supplemental Content

Support Center